Gene Flow and Individual Relatedness Suggest Population Spatial Connectivity of Sinogastromyzon sichangensis (Cypriniformes: Balitoridae) in the Chishui River, China

| Steven WashingtonSteven Washington | 0 Comment
stjosephs-hospital

 

  • Sinogastromyzon sichangensisis a hillstream loach endemic to the upper Yangtze River, China. It is unclear whether this fish lives in a very restricted area or may be dispersed over a long distance. In the present study spatial connectivity of populations of  sichangensis was investigated based on 343 individuals collected from 12 sites of Chishui River and employing 22 microsatellite loci.
  • The results of genetic diversity analysis showed that observed heterozygosity (HO) and polymorphism information content (PIC) ranged from 0.5653 to 0.6999 and 0.8513 to 0.8819, respectively. Population structure analysis suggested that  sichangensishad an unclear genetic structure. AMOVA showed that 69.36% of genetic variation was attributed to differentiation within individuals and all the pairwise genetic differentiation indices (FST) were low (mean FST = 0.0344), indicating weak differentiation among these populations.
  • Estimation of gene flow showed frequent flow among populations, and contemporary levels (mean contemporary migration rate, mc= 0.0131) were approximately equal to historical levels (mean historical migration rate, mh = 0.0147).
  • Individual relatedness analysis revealed a high level of sibship within and among different populations. The frequent gene flow and widespread sibship were due to  sichangensislaying drifting eggs which travel for a long distance until hatching, after which the juveniles or adults migrate upstream. The results of unclear geographic structure and frequent exchange also indicate that it is necessary to decrease the negative impacts of anthropogenic activities on the connectivity of rivers to protect the migration routes of S. sichangensis.

 

Case Report: Identification of a Novel Variant (m.8909T>C) of Human Mitochondrial ATP6 Gene and Its Functional Consequences on Yeast ATP Synthase

 

With the advent of next generation sequencing, the list of mitochondrial DNA (mtDNA) mutations identified in patients rapidly and continuously expands. They are frequently found in a limited number of cases, sometimes a single individual (as with the case herein reported) and in heterogeneous genetic backgrounds (heteroplasmy), which makes it difficult to conclude about their pathogenicity and functional consequences.

As an organism amenable to mitochondrial DNA manipulation, able to survive by fermentation to loss-of-function mtDNA mutations, and where heteroplasmy is unstable, Saccharomyces cerevisiae is an excellent model for investigating novel human mtDNA variants, in isolation and in a controlled genetic context. We herein report the identification of a novel variant in mitochondrial ATP6 gene, m.8909T>C. It was found in combination with the well-known pathogenic m.3243A>G mutation in mt-tRNALeu.

We show that an equivalent of the m.8909T>C mutation compromises yeast adenosine tri-phosphate (ATP) synthase assembly/stability and reduces the rate of mitochondrial ATP synthesis by 20-30% compared to wild type yeast. Other previously reported ATP6 mutations with a well-established pathogenicity (like m.8993T>C and m.9176T>C) were shown to have similar effects on yeast ATP synthase. It can be inferred that alone the m.8909T>C variant has the potential to compromise human health.

Investigating the Role of Telomere and Telomerase Associated Genes and Proteins in Endometrial Cancer

 

  • Endometrial cancer (EC) is the commonest gynaecological malignancy. Current prognostic markers are inadequate to accurately predict patient survival, necessitating novel prognostic markers, to improve treatment strategies. Telomerase has a unique role within the endometrium, whilst aberrant telomerase activity is a hallmark of many cancers.
  • The aim of the current in silico study is to investigate the role of telomere and telomerase associated genes and proteins (TTAGPs) in EC to identify potential prognostic markers and therapeutic targets. Analysis of RNA-seq data from The Cancer Genome Atlas identified differentially expressed genes (DEGs) in EC (568 TTAGPs out of 3467) and ascertained DEGs associated with histological subtypes, higher grade endometrioid tumours and late stage EC.
  • Functional analysis demonstrated that DEGs were predominantly involved in cell cycle regulation, while the survival analysis identified 69 DEGs associated with prognosis. The protein-protein interaction network constructed facilitated the identification of hub genes, enriched transcription factor binding sites and drugs that may target the network.
  • Thus, our in silico methods distinguished many critical genes associated with telomere maintenance that were previously unknown to contribute to EC carcinogenesis and prognosis, including NOP56, WFS1, ANAPC4and TUBB4A. Probing the prognostic and therapeutic utility of these novel TTAGP markers will form an exciting basis for future research.
stjosephs-hospital

stjosephs-hospital

CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

 

Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients,

a so called “adoptive cell transfer”, or ACT, process. Construction of allogeneic T-cells is dependent on the employment of a gene-editing tool to modify donor-extracted T-cells and prepare them to specifically act against tumor cells with enhanced function and durability and least side-effects. In this context, CRISPR technology can be used to produce universal T-cells, equipped with recombinant T cell receptor (TCR) or chimeric antigen receptor (CAR), through multiplex genome engineering using Cas nucleases.

The robust potential of CRISPR-Cas in preparing the building blocks of ACT immunotherapy has broaden the application of such therapies and some of them have gotten FDA approvals. Here, we have collected the last investigations in the field of immuno-oncology conducted in partnership with CRISPR technology. In addition, studies that have addressed the challenges in the path of CRISPR-mediated cancer immunotherapy, as well as pre-treatment applications of CRISPR-Cas have been mentioned in detail.

Deregulated microRNAs Are Associated with Patient Survival and Predicted to Target Genes That Modulate Lung Cancer Signaling Pathways

 

Background: Although the advances in diagnostic and treatment strategies, lung cancer remains the leading cause of cancer-related deaths, worldwide, with survival rates as low as 16% in developed countries. Low survival rates are mainly due to late diagnosis and the lack of effective treatment. Therefore, the identification of novel, clinically useful biomarkers is still needed for patients with advanced disease stage and poor survival.

Micro(mi)RNAs are non-coding RNAs and potent regulators of gene expression with a possible role as diagnostic, prognostic and predictive biomarkers in cancer.

Methods: We applied global miRNA expression profiling analysis using TaqMan® arrays in paired tumor and normal lung tissues (n = 38) from treatment-naïve patients with lung adenocarcinoma (AD; n = 23) and lung squamous cell carcinoma (SCC; n = 15). miRNA target genes were validated using The Cancer Genome Atlas (TCGA) lung AD (n = 561) and lung SCC (n = 523) RNA-Seq datasets.

Results: We identified 33 significantly deregulated miRNAs (fold change, FC ≥ 2.0 and p < 0.05) in tumors relative to normal lung tissues, regardless of tumor histology. Enrichment analysis confirmed that genes targeted by the 33 miRNAs are aberrantly expressed in lung AD and SCC, and modulate known pathways in lung cancer. Additionally, high expression of miR-25-3p was significantly associated (p < 0.05) with poor patient survival, when considering both tumor histologies.

Conclusions: miR-25-3p may be a potential prognostic biomarker in non-small cell lung cancer. Genes targeted by miRNAs regulate EGFR and TGFβ signaling, among other known pathways relevant to lung tumorigenesis.

 

FOS-B Human Recombinant
rAP-4393 Inquiry Ask for price

FOS-B Human Recombinant Protein
PROTP53539 Regular: 5ug
EUR 574.8
Description: FOS-B Human Recombinant (a.a. 113-151) expressed in E.coli, shows a 32 kDa SDS-PAGE (Including GST).;The FOS-B is purified by proprietary chromatographic techniques.

Recombinant (E.Coli, GST) Human FOS-B
RP-945 2 ug
EUR 416.4

Fos B
GWB-69F0E1 0.01 mg Ask for price

Fos B (FOSB) (NM_006732) Human Over-expression Lysate
LS002354 100ug
EUR 628
Description: Transient overexpression lysate of FBJ murine osteosarcoma viral oncogene homolog B (FOSB), transcript variant 1

c Fos (FOS) (NM_005252) Human Over-expression Lysate
LS002353 100ug
EUR 628
Description: Transient overexpression lysate of FBJ murine osteosarcoma viral oncogene homolog (FOS)

FOS siRNA (Human)
MBS8238706-15nmol 15nmol
EUR 405

FOS siRNA (Human)
MBS8238706-30nmol 30nmol
EUR 565

FOS siRNA (Human)
MBS8238706-5x30nmol 5x30nmol
EUR 2450

Human Proto- oncogene c- Fos, FOS ELISA KIT
ELI-04266h 96tests
EUR 696

FOS B antibody
29246 100ul
EUR 319

FOS B antibody
29246-100ul 100ul
EUR 302.4

FOS B antibody
MBS9402227-005mL 0.05mL
EUR 245

FOS B antibody
MBS9402227-01mL 0.1mL
EUR 305

FOS B antibody
MBS9402227-5x01mL 5x0.1mL
EUR 1230

Fos B Antibody
B0930-100ul 100μl
EUR 217
Description: Fos B Rabbit Polyclonal Antibody

Fos B Antibody
B0930-50ul 50μl
EUR 143.5
Description: Fos B Rabbit Polyclonal Antibody

Recombinant Human FOS-B Protein, Untagged, E.coli-2ug
QP11898-2ug 2ug
EUR 294

Recombinant Human FOS-B Protein, Untagged, E.coli-5ug
QP11898-5ug 5ug
EUR 403.2

Recombinant Human FOS-B Protein, Untagged, E.coli-10ug
QP11898-10ug 10ug
EUR 663.6

Recombinant Human Proto-oncogene c-Fos (FOS)
MBS959009-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1250

Recombinant Human Proto-oncogene c-Fos (FOS)
MBS959009-002mgEColi 0.02mg(E-Coli)
EUR 915

Recombinant Human Proto-oncogene c-Fos (FOS)
MBS959009-002mgYeast 0.02mg(Yeast)
EUR 1040

Recombinant Human Proto-oncogene c-Fos (FOS)
MBS959009-01mgEColi 0.1mg(E-Coli)
EUR 1100

Recombinant Human Proto-oncogene c-Fos (FOS)
MBS959009-01mgYeast 0.1mg(Yeast)
EUR 1185

Human FOS ELISA Kit
EHF0120 96Tests
EUR 625.2

Human FOS ELISA Kit
ELA-E1291h 96tests
EUR 696

Human FOS ELISA KIT
EF005100 96tests
EUR 566

Human FOS ELISA Kit
IHUFOSKT each
EUR 548
Description: Human FOS ELISA Kit

Human FOS ELISA Kit
MBS8427163-INQUIRE INQUIRE Ask for price

Rabbit Polyclonal (IgG) to Human FOS / c-FOS
MBS247088-005mL 0.05mL
EUR 595

Rabbit Polyclonal (IgG) to Human FOS / c-FOS
MBS247088-5x005mL 5x0.05mL
EUR 2500

Human Proto-Oncogene C-Fos (FOS) CLIA Kit
20-abx492601
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Human Proto-Oncogene C-Fos (FOS) ELISA Kit
20-abx151580
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Human Proto-oncogene c-Fos (FOS) ELISA Kit
abx570165-96tests 96 tests
EUR 801.6

Human FOS/ Proto-oncogene c-Fos ELISA Kit
E0936Hu 1 Kit
EUR 515
Description: G0S7,Cellular oncogene fos,G0/G1 switch regulatory protein 7

Human FOS(Proto-oncogene c-Fos) ELISA Kit
EH1465 96T
EUR 681.12
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.188 ng/ml

Human FOS(Proto-oncogene c-Fos) ELISA Kit
EKF58552-48T 48T
EUR 396.9

Human FOS(Proto-oncogene c-Fos) ELISA Kit
EKF58552-5x96T 5x96T
EUR 2693.25

Human FOS(Proto-oncogene c-Fos) ELISA Kit
EKF58552-96T 96T
EUR 567

Human Proto-oncogene c-Fos,fos ELISA KIT
E0614Hu-1096T 10*96T
EUR 4122

Human Proto-oncogene c-Fos,fos ELISA KIT
E0614Hu-48wells 48 wells
EUR 300

Human Proto-oncogene c-Fos,fos ELISA KIT
E0614Hu-596T 5*96T
EUR 2061

Human Proto-oncogene c-Fos,fos ELISA KIT
E0614Hu-96wells 96 wells
EUR 458

Human Proto-oncogene c-Fos (FOS) ELISA Kit
RK07956 96T
EUR 280

Human FOS / Proto-oncogene c-Fos ELISA Kit
E1291h 96T
EUR 736

Human FOS shRNA Plasmid
20-abx951644
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Human FOS Protein Lysate
MBS8411880-002mg 0.02mg
EUR 365

Human FOS Protein Lysate
MBS8411880-5x002mg 5x0.02mg
EUR 1410

Fos B Rabbit mAb
58812 100ul
EUR 339

Fos B Rabbit pAb
E2381043 100ul
EUR 225
Description: Available in various conjugation types.

Fos B Rabbit mAb
A24339 200μL
EUR 323.7
Description: A synthetic peptide corresponding to a sequence within amino acids 371-470 of human Desmin (P17661).

Fos B Rabbit mAb
E2R381043 100ul
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Fos B Rabbit pAb
MBS8542508-01mL 0.1mL
EUR 305

Fos B Rabbit pAb
MBS8542508-01mLAF405L 0.1mL(AF405L)
EUR 565

Fos B Rabbit pAb
MBS8542508-01mLAF405S 0.1mL(AF405S)
EUR 565

Fos B Rabbit pAb
MBS8542508-01mLAF610 0.1mL(AF610)
EUR 565

Fos B Rabbit pAb
MBS8542508-01mLAF635 0.1mL(AF635)
EUR 565

FOS Recombinant Protein (Human)
RP012430 100 ug Ask for price

Recombinant Human FOS protein
MBS1561989-005mg 0.05mg
EUR 320

Recombinant Human FOS protein
MBS1561989-01mg 0.1mg
EUR 410

Recombinant Human FOS protein
MBS1561989-5x01mg 5x0.1mg
EUR 1520

Human FBJ Murine Osteosarcoma Viral Oncogene Homolog B,FOS-B ELISA KIT
E4679Hu-1096T 10*96T
EUR 4122

Human FBJ Murine Osteosarcoma Viral Oncogene Homolog B,FOS-B ELISA KIT
E4679Hu-48wells 48 wells
EUR 300

Human FBJ Murine Osteosarcoma Viral Oncogene Homolog B,FOS-B ELISA KIT
E4679Hu-596T 5*96T
EUR 2061

Human FBJ Murine Osteosarcoma Viral Oncogene Homolog B,FOS-B ELISA KIT
E4679Hu-96wells 96 wells
EUR 458

Human FBJ Murine Osteosarcoma Viral Oncogene Homolog B, FOS-B ELISA Kit
MBS1602893-10x96StripWells 10x96-Strip-Wells
EUR 3460

Human FBJ Murine Osteosarcoma Viral Oncogene Homolog B, FOS-B ELISA Kit
MBS1602893-48StripWells 48-Strip-Wells
EUR 285

Human FBJ Murine Osteosarcoma Viral Oncogene Homolog B, FOS-B ELISA Kit
MBS1602893-5x96StripWells 5x96-Strip-Wells
EUR 1750

Human FBJ Murine Osteosarcoma Viral Oncogene Homolog B, FOS-B ELISA Kit
MBS1602893-96StripWells 96-Strip-Wells
EUR 425

Fos B Polyclonal Antibody
ABP51360-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of Fos B from Human, Mouse, Monkey. This Fos B antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Fos B around the non-phosphorylation site of S27

Fos B Polyclonal Antibody
ABP51360-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of Fos B from Human, Mouse, Monkey. This Fos B antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Fos B around the non-phosphorylation site of S27

Fos B Polyclonal Antibody
ABP51360-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of Fos B from Human, Mouse, Monkey. This Fos B antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Fos B around the non-phosphorylation site of S27

Fos B Polyclonal Antibody
E20-71738 100ug
EUR 225
Description: Available in various conjugation types.

FOS B Conjugated Antibody
C29246 100ul
EUR 476.4

Fos B Polyclonal Antibody
E44H02228 100ul
EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Fos B Polyclonal Antibody
BT-AP03304-100ul 100ul Ask for price
Description: The Fos gene family consists of 4 members: fOS, FOSB, FOSL1, and FOSL2. These genes encode leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1. As such, the FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. Alternatively spliced transcript variants encoding different isoforms have been found for FOSB.

Fos B Polyclonal Antibody
BT-AP03304-20ul 20ul Ask for price
Description: The Fos gene family consists of 4 members: fOS, FOSB, FOSL1, and FOSL2. These genes encode leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1. As such, the FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. Alternatively spliced transcript variants encoding different isoforms have been found for FOSB.

Fos B Polyclonal Antibody
BT-AP03304-50ul 50ul Ask for price
Description: The Fos gene family consists of 4 members: fOS, FOSB, FOSL1, and FOSL2. These genes encode leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1. As such, the FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. Alternatively spliced transcript variants encoding different isoforms have been found for FOSB.

Fos B Polyclonal Antibody
MBS9243678-01mL 0.1mL
EUR 415

Fos B Polyclonal Antibody
MBS9243678-5x01mL 5x0.1mL
EUR 1841

Fos B Polyclonal Antibody
MBS8522719-01mg 0.1mg
EUR 305

Fos B Polyclonal Antibody
MBS8522719-01mLAF405L 0.1mL(AF405L)
EUR 465

Fos B Polyclonal Antibody
MBS8522719-01mLAF405S 0.1mL(AF405S)
EUR 465

Fos B Polyclonal Antibody
MBS8522719-01mLAF610 0.1mL(AF610)
EUR 465

Fos B Polyclonal Antibody
MBS8522719-01mLAF635 0.1mL(AF635)
EUR 465

Fos B Polyclonal Antibody
MBS2537747-002mL 0.02mL
EUR 140

Fos B Polyclonal Antibody
MBS2537747-006mL 0.06mL
EUR 180

Fos B Polyclonal Antibody
MBS2537747-012mL 0.12mL
EUR 260

Fos B Polyclonal Antibody
MBS2537747-02mL 0.2mL
EUR 405
Steven Washington

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Related Post

stjosephs-hospital

A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaA Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Background: Induction chemotherapy (IC) adopted by concurrent chemoradiotherapy is the mainstay remedy for sufferers with locoregionally superior nasopharyngeal carcinoma. Nevertheless, some sufferers acquire little profit and expertise pointless poisonousities from IC.

READ MOREREAD MORE